Patents by Inventor Mario Cardozo
Mario Cardozo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951133Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.Type: GrantFiled: July 13, 2022Date of Patent: April 9, 2024Assignee: NURIX THERAPEUTICS, INC.Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
-
Publication number: 20230212186Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.Type: ApplicationFiled: December 19, 2022Publication date: July 6, 2023Inventors: Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Hunter SHUNATONA, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING
-
Publication number: 20230150991Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.Type: ApplicationFiled: June 29, 2022Publication date: May 18, 2023Inventors: Arthur T. SANDS, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
-
Patent number: 11530229Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.Type: GrantFiled: May 15, 2020Date of Patent: December 20, 2022Assignee: NURIX THERAPEUTICS, INC.Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
-
Publication number: 20220387395Abstract: Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.Type: ApplicationFiled: July 27, 2020Publication date: December 8, 2022Inventors: Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Morgan LAWRENZ, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING
-
Publication number: 20220378839Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.Type: ApplicationFiled: July 13, 2022Publication date: December 1, 2022Inventors: Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Hunter SHUNATONA, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING
-
Publication number: 20220324835Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.Type: ApplicationFiled: January 25, 2019Publication date: October 13, 2022Inventors: Paul A. BARSANTI, Neil F. BENCE, Jennifa GOSLING, Anjanabha SAHA, Asad M TAHERBHOY, Christoph W. ZAPF, Kathleen BOYLE, Mario CARDOZO, Jeffrey MIHALIC, Morgan LAWRENZ, Mark GALLOP, Jilliane BRUFFEY, Thomas CUMMINS, Daniel ROBBINS, Hiroko TANAKA, Chenbo WANG, Frederick COHEN, Wylie PALMER, Arthur T. SANDS, Hunter SHUNATONA
-
Patent number: 11464802Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.Type: GrantFiled: April 9, 2020Date of Patent: October 11, 2022Assignee: Nurix Therapeutics, Inc.Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
-
Patent number: 11401267Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.Type: GrantFiled: June 26, 2020Date of Patent: August 2, 2022Assignee: NURIX THERAPEUTICS, INC.Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
-
Publication number: 20210053961Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.Type: ApplicationFiled: June 26, 2020Publication date: February 25, 2021Inventors: Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Hunter SHUNATONA, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING
-
Publication number: 20210053986Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.Type: ApplicationFiled: May 15, 2020Publication date: February 25, 2021Inventors: Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Hunter SHUNATONA, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING
-
Publication number: 20200323904Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.Type: ApplicationFiled: April 9, 2020Publication date: October 15, 2020Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss
-
Publication number: 20070244155Abstract: Compounds having the general formula I and/or the general formula II are useful, for example, for treating metabolic disorders in a subject where the variables are provided herein. Compositions and methods for using the compounds for preparing medicaments and for treating metabolic disorders such as, for instance, type II diabetes are disclosed.Type: ApplicationFiled: March 13, 2007Publication date: October 18, 2007Applicant: AMGEN INC.Inventors: Rajiv Sharma, Michelle Akerman, Mario Cardozo, Jonathan Houze, An-Rong Li, Jinquian Liu, Jiwen Liu, Zhihua Ma, Julio Medina, Michael Schmitt, Ying Sun, Yingcai Wang, Zhongyu Wang, Liusheng Zhu
-
Publication number: 20070155777Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.Type: ApplicationFiled: February 21, 2007Publication date: July 5, 2007Applicants: Tularik Inc.Inventors: Simon Burkitt, Mario Cardozo, Timothy Cushing, Michael DeGraffeneid, Christopher Farthing, Xiaolin Hao, Juan Jaen, Xian Jiao, David Kopecky, Marc Labelle, Sarah Lively, Dustin McMinn, Sven Rasmussen, Youngsook Shin, Andrew Smith, Marie-Louise Smith
-
Publication number: 20070072851Abstract: The present invention relates to compounds of Formula I or a stereomer, a tautomer, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof, pharmaceutical formulations containing the compounds, methods of treatments using the compounds, for example, protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders and methods of preparing medicaments comprising the compounds.Type: ApplicationFiled: August 18, 2006Publication date: March 29, 2007Applicant: Amgen Inc.Inventors: John Buchanan, William Buckner, Mario Cardozo, Erin DiMauro, Jiasheng Fu, Xiaolin Hao, Xian Jiao, Frank Kayser, David Kopecky, Craig Masse, Susan Tomlinson, Ryan White, Xiaotian Zhu
-
Publication number: 20060293292Abstract: Disclosed are hydrazine compounds useful as soluble epoxide hydrolase (sEH) inhibitors for treating cardiovascular diseases.Type: ApplicationFiled: May 1, 2006Publication date: December 28, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Mario CARDOZO, Richard INGRAHAM
-
Publication number: 20060276515Abstract: Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.Type: ApplicationFiled: May 1, 2006Publication date: December 7, 2006Inventors: Charles Cywin, Stephane De Lombaert, Anne Eldrup, Richard Ingraham, Fariba Soleymanzadeh, Steven Taylor, Mario Cardozo
-
Publication number: 20050282881Abstract: Compounds of Formula (IA) wherein R1, R2, R3, R4 and R5 are as defined herein for Formula (IA), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.Type: ApplicationFiled: July 20, 2005Publication date: December 22, 2005Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Younes Bekkali, Rajashehar Betageri, Mario Cardozo, Thomas Gilmore, Thomas Kirrane, Daniel Kuzmich, John Proudfoot, Hidenori Takahashi, David Thomson, Renee Zindell
-
Publication number: 20050124002Abstract: A method for determining efficient synthesis of chemical compounds forming a chemical library, such as a library generated using combinatorial chemistry, is described and disclosed involving the generation of ordered sub-sets of compounds from such library in order to rank or choose which compounds to be synthesized based on reagents to be used.Type: ApplicationFiled: January 18, 2005Publication date: June 9, 2005Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Mario Cardozo, Edward Graham, Stephen Jacober
-
Publication number: 20050124640Abstract: Disclosed are novel compounds of formula (I): wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: September 3, 2004Publication date: June 9, 2005Applicants: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Mario Cardozo, Derek Cogan, Charles Cywin, George Dahmann, Darren DiSalvo, John Ginn, Anthony Prokopowicz, Denice Spero, Erick Young